CAR-T / CRS Cytokine Multiplex ELISA Kit is launched
CAR-T / CRS Cytokine Multiplex ELISA Kit is launched
CAR-T cell therapy is a type of immunotherapy that shows a remarkable success in treating hematologic cancers. However, it is associated with severe and occasionally lethal toxicities. CRS is the most common clinical complication. To monitor CRS and understand the mechanism of CRS are critical to manage CRS and improve the treatment strategies of CAR-T cell therapy.
▶ About CAR-T
Chimeric antigen receptor (CAR) T cell therapy is a type of cellular immunotherapy that redirects patient's or donor's’s T cells to recognize and destroy cancer cells. CAR consists of an antibody-derived targeting domain fused with T-cell signaling domains that endows the T-cell with the recognition of tumor-specific antigen. The CAR-T cells are generated by collecting T cells from patient or donor and engineering them by incorporation of CAR. The expanded CAR-T cells are then reinjected into patient for fighting cancer cells.
▶ CRS, a severe side effect of CAR-T cell therapy
Upon recognizing tumor-specific antigen, CAR-T cells mediate cytotoxicity as well as secrete pro-inflammatory cytokines that in turn stimulate massive cytokine production leading to cytokine release syndrome (CRS). CRS is characterized by fever, difficulty breathing, hyperinflammation, and severe organ dysfunction. Severe CRS is a life-threatening complication. Therefore, to monitor the cytokine levels is critical to manage CRS.
▶ Monitoring CAR-T induced CRS
When activated by binding to tumor cells, CAR-T cells secrete IL-2 to maintain their survival and function as well as IFNγ and TNFα to stimulate the secretion of inflammatory cytokines from monocytes and macrophages. Meanwhile, the destroyed tumor cells release large amounts of DAMPs that activate macrophages to produce massive cytokines leading to CRS. Researchers found that cytokines including IFNγ, IL-2, IL-6, and IL-10 were significantly higher in patients who experience severe CRS.
arigo's Human CAR-T / CRS Cytokine Multiplex ELISA Kit (ARG82969) allows a concurrent measurement of the 4 key cytokines IFNγ, IL-2, IL-6, and IL-10 . It is the best solution to study the CAR-T induced CRS.
| Multiplex ELISA Kit | Sensitivity |
| Human CAR-T / CRS Cytokine Multiplex ELISA Kit (ARG82969) |
IFNγ: 15.625 pg/ml IL-2: 15.625 pg/ml IL-6: 31.25 pg/ml IL-10: 15.625 pg/ml |
▶ More biomarkers for CAR-T induced CRS
| ELISA Kit | Sensitivity |
| Human CRP ELISA Kit (ARG80195) | 1.6 ng/ml |
| Human Ferritin ELISA Kit (ARG80501) | 0.4 ng/ml |
| Triglyceride Assay Kit (ARG81628) | 0.01 mmol/L |
| Human Pro-inflammatory Cytokine Multiplex ELISA Kit (ARG82862) |
IL-1β: 4 pg/ml IL-6: 5 pg/ml TNFα: 8 pg/ml IFNγ: 4 pg/ml |
| Human GM-CSF ELISA Kit (ARG80122) | 8 pg/ml |
| Human MCP-1 ELISA Kit (ARG80128) | 8 pg/ml |
| Human MIP1α ELISA Kit (ARG80167) | 15.6 pg/ml |
